Nine Months Later, China Compliance Crackdown No Longer As Feared
This article was originally published in PharmAsia News
Executive Summary
Nearly nine months after the beginning of compliance scandals involving drug makers in China, the international industry appears to have decided the negative impact was not as long-lasting as feared.
Nearly nine months after the beginning of compliance scandals involving drug makers in China, the international industry appears to have decided the negative impact was not as long-lasting as feared. The first case in China's crackdown on bribery and other corruption involving drug makers involved GlaxoSmithKline, which remained the one hit the hardest as the investigation of its activities continues. But others reported their initial concerns had eased. Some drug makers believe GSK was singled out by the government to serve as an example of its seriousness. (Click here for more
)
"Big Pharma's Rise In China Not Held Back By Scandals" - Financial Times (U.K.) (4/2/2014)